<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=Hypersensitivity_pneumonitis</id>
	<title>Hypersensitivity pneumonitis - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=Hypersensitivity_pneumonitis"/>
	<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Hypersensitivity_pneumonitis&amp;action=history"/>
	<updated>2026-04-20T03:42:34Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.38.2</generator>
	<entry>
		<id>https://wikem.org/w/index.php?title=Hypersensitivity_pneumonitis&amp;diff=389175&amp;oldid=prev</id>
		<title>Danbot: Strip excess bold</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Hypersensitivity_pneumonitis&amp;diff=389175&amp;oldid=prev"/>
		<updated>2026-03-22T09:28:54Z</updated>

		<summary type="html">&lt;p&gt;Strip excess bold&lt;/p&gt;
&lt;a href=&quot;//wikem.org/w/index.php?title=Hypersensitivity_pneumonitis&amp;amp;diff=389175&amp;amp;oldid=386216&quot;&gt;Show changes&lt;/a&gt;</summary>
		<author><name>Danbot</name></author>
	</entry>
	<entry>
		<id>https://wikem.org/w/index.php?title=Hypersensitivity_pneumonitis&amp;diff=386216&amp;oldid=prev</id>
		<title>Danbot: Moved intro into Background as bullets; removed excessive bold from bullet lead-ins; added Pulmonary fibrosis differential and Cough DDX templates</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Hypersensitivity_pneumonitis&amp;diff=386216&amp;oldid=prev"/>
		<updated>2026-03-19T14:42:34Z</updated>

		<summary type="html">&lt;p&gt;Moved intro into Background as bullets; removed excessive bold from bullet lead-ins; added Pulmonary fibrosis differential and Cough DDX templates&lt;/p&gt;
&lt;a href=&quot;//wikem.org/w/index.php?title=Hypersensitivity_pneumonitis&amp;amp;diff=386216&amp;amp;oldid=386015&quot;&gt;Show changes&lt;/a&gt;</summary>
		<author><name>Danbot</name></author>
	</entry>
	<entry>
		<id>https://wikem.org/w/index.php?title=Hypersensitivity_pneumonitis&amp;diff=386015&amp;oldid=prev</id>
		<title>Ostermayer: Created page with &quot;Hypersensitivity pneumonitis (HP), formerly known as extrinsic allergic alveolitis, is an immune-mediated interstitial lung disease caused by an exaggerated inflammatory response to repeated inhalation of a sensitizing antigen in a susceptible host.&lt;ref name=&quot;ATS2020&quot;&gt;Raghu G, et al. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. ''Am J Respir Crit Care Med''. 2020;202(3):e36-e69.&lt;/ref&gt; More than 300 causative a...&quot;</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Hypersensitivity_pneumonitis&amp;diff=386015&amp;oldid=prev"/>
		<updated>2026-03-11T12:06:59Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;Hypersensitivity pneumonitis (HP), formerly known as extrinsic allergic alveolitis, is an immune-mediated interstitial lung disease caused by an exaggerated inflammatory response to repeated inhalation of a sensitizing antigen in a susceptible host.&amp;lt;ref name=&amp;quot;ATS2020&amp;quot;&amp;gt;Raghu G, et al. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. &amp;#039;&amp;#039;Am J Respir Crit Care Med&amp;#039;&amp;#039;. 2020;202(3):e36-e69.&amp;lt;/ref&amp;gt; More than 300 causative a...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Hypersensitivity pneumonitis (HP), formerly known as extrinsic allergic alveolitis, is an immune-mediated interstitial lung disease caused by an exaggerated inflammatory response to repeated inhalation of a sensitizing antigen in a susceptible host.&amp;lt;ref name=&amp;quot;ATS2020&amp;quot;&amp;gt;Raghu G, et al. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. ''Am J Respir Crit Care Med''. 2020;202(3):e36-e69.&amp;lt;/ref&amp;gt; More than 300 causative antigens have been identified.&amp;lt;ref name=&amp;quot;ALA&amp;quot;&amp;gt;Hypersensitivity Pneumonitis. American Lung Association.&amp;lt;/ref&amp;gt; The disease exists on a spectrum from acute self-limiting inflammation to irreversible pulmonary fibrosis indistinguishable from [[idiopathic pulmonary fibrosis]] (IPF). '''Antigen avoidance is the cornerstone of management'''&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;&amp;gt;Hypersensitivity Pneumonitis. ''StatPearls''. NCBI Bookshelf. Updated July 2023.&amp;lt;/ref&amp;gt; — the ED physician's most important role is to consider the diagnosis, obtain a thorough exposure history, and initiate appropriate workup.&lt;br /&gt;
&lt;br /&gt;
==Background==&lt;br /&gt;
*Combination of type III (immune complex) and type IV (delayed-type/cell-mediated) hypersensitivity reactions&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;/&amp;gt;&lt;br /&gt;
*Inflammation is '''bronchiolocentric''' — centered on the small airways due to the inhalational route of injury&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;/&amp;gt;&lt;br /&gt;
*Pathologic hallmark: '''poorly formed, non-caseating granulomas''' with lymphocytic infiltration around bronchioles (distinct from sarcoidosis, which has well-formed granulomas along the bronchovascular bundle)&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;/&amp;gt;&lt;br /&gt;
*Cigarette smoking is paradoxically '''protective''' — nicotine inhibits macrophage activation and lymphocyte proliferation; however, smokers who do develop HP tend to have more fibrotic disease&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;/&amp;gt;&lt;br /&gt;
*Genetic susceptibility through MHC class II (HLA-DR and HLA-DQ) polymorphisms&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;/&amp;gt;&lt;br /&gt;
*Incidence: ~1–2 per 100,000 person-years; accounts for 1.5–12% of all interstitial lung diseases&amp;lt;ref name=&amp;quot;Merck&amp;quot;&amp;gt;Hypersensitivity Pneumonitis. ''Merck Manual Professional Edition''. Updated 2025.&amp;lt;/ref&amp;gt;&lt;br /&gt;
*'''Current classification (ATS/JRS/ALAT 2020):''' Two phenotypes replace the older acute/subacute/chronic terminology&amp;lt;ref name=&amp;quot;ATS2020&amp;quot;/&amp;gt;&lt;br /&gt;
**'''Non-fibrotic HP:''' Inflammatory, often reversible with antigen avoidance ± corticosteroids&lt;br /&gt;
**'''Fibrotic HP:''' Established fibrosis present on imaging or biopsy; worse prognosis; may progress to end-stage lung disease&lt;br /&gt;
*'''Common exposures and eponyms:'''&lt;br /&gt;
**'''Farmer's lung''' — thermophilic ''Actinomycetes'' (''Saccharopolyspora rectivirgula'') in moldy hay, grain, straw; the prototype of HP&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;/&amp;gt;&lt;br /&gt;
**'''Bird fancier's lung''' (pigeon breeder's disease) — avian proteins in droppings, feathers, serum; '''most common form of HP worldwide''' (66–68% of all cases); 5-year mortality ~30% (worse prognosis than farmer's lung due to persistent domestic antigen exposure)&amp;lt;ref name=&amp;quot;Medscape&amp;quot;&amp;gt;Hypersensitivity Pneumonitis. ''Medscape/eMedicine''. Updated 2024.&amp;lt;/ref&amp;gt;&lt;br /&gt;
**'''Hot tub lung''' — ''Mycobacterium avium'' complex (MAC) in aerosolized warm water; may represent true infection vs. HP (debated)&amp;lt;ref name=&amp;quot;Medscape&amp;quot;/&amp;gt;&lt;br /&gt;
**'''Humidifier lung''' — ''Thermoactinomyces'', ''Cladosporium'' in contaminated HVAC systems, humidifiers&lt;br /&gt;
**'''Chemical worker's lung''' — isocyanates (toluene diisocyanate, MDI), zinc, nickel; low-molecular-weight haptens that form antigenic complexes with host proteins&amp;lt;ref name=&amp;quot;Merck&amp;quot;/&amp;gt;&lt;br /&gt;
**Others: Mushroom worker's lung, maple bark disease, malt worker's lung (''Aspergillus clavatus''), saxophone lung (''Candida''/''Ulocladium'' in mouthpieces), metalworking fluid HP, cheese worker's lung&lt;br /&gt;
**'''Feather bedding HP''' — indirect bird antigen exposure from down pillows and duvets; easily missed on history&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;/&amp;gt;&lt;br /&gt;
*Farming, bird contact, and water contamination account for ~75% of cases&amp;lt;ref name=&amp;quot;Merck&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Features==&lt;br /&gt;
'''Acute/non-fibrotic HP''' (high-dose, intermittent exposure):&lt;br /&gt;
*Symptoms begin '''4–8 hours''' after antigen exposure (key historical clue)&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;/&amp;gt;&lt;br /&gt;
*Fever, chills, malaise, myalgias, dry cough, dyspnea — often misdiagnosed as '''flu-like illness''' or [[pneumonia]]&lt;br /&gt;
*Symptoms typically resolve within '''1–2 days''' of avoiding exposure&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;/&amp;gt;&lt;br /&gt;
*Recurrent stereotyped episodes temporally linked to a specific environment are highly suggestive&lt;br /&gt;
*Exam: fever, tachypnea, bibasal '''fine inspiratory crackles'''; wheeze is uncommon&amp;lt;ref name=&amp;quot;PatientInfo&amp;quot;&amp;gt;Extrinsic Allergic Alveolitis. ''Patient.info''. Updated August 2024.&amp;lt;/ref&amp;gt;&lt;br /&gt;
*'''Severe acute HP''' can cause life-threatening respiratory failure with cyanosis and respiratory distress at rest&amp;lt;ref name=&amp;quot;PatientInfo&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Chronic/fibrotic HP''' (low-dose, prolonged exposure):&lt;br /&gt;
*'''Insidious onset''' of progressive dyspnea, chronic dry cough, fatigue, weight loss&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;/&amp;gt;&lt;br /&gt;
*Often '''no history of acute episodes''' — the intermittent febrile response may be absent&lt;br /&gt;
*No clear temporal link to exposure (antigen exposure may be continuous and low-level)&lt;br /&gt;
*Exam: tachypnea, inspiratory crackles (particularly bibasal), '''clubbing in up to 50%''' of chronic cases&amp;lt;ref name=&amp;quot;Wikipedia&amp;quot;&amp;gt;Hypersensitivity pneumonitis. ''Wikipedia''. Updated September 2025.&amp;lt;/ref&amp;gt;&lt;br /&gt;
*Late findings: cyanosis, signs of [[pulmonary hypertension]] and right heart failure&lt;br /&gt;
*May be clinically and radiologically '''indistinguishable from IPF'''&amp;lt;ref name=&amp;quot;ATS2020&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Key history questions for the ED:'''&lt;br /&gt;
*Occupation (farming, bird handling, factory work, metalworking, brewing, woodworking)&lt;br /&gt;
*Hobbies (bird keeping, pigeon racing, hot tub use, gardening/composting)&lt;br /&gt;
*Home environment (feather bedding/pillows, visible mold, water damage, humidifiers, HVAC maintenance, pet birds, indoor hot tub)&lt;br /&gt;
*Timing of symptoms relative to specific environments — '''do symptoms improve on weekends, vacations, or hospitalizations?'''&lt;br /&gt;
*New exposures (recently acquired birds, new home, new workplace, CPAP/BiPAP equipment)&lt;br /&gt;
&lt;br /&gt;
==Differential Diagnosis==&lt;br /&gt;
'''Acute HP differential:'''&lt;br /&gt;
*[[Pneumonia]] (community-acquired — the most common initial misdiagnosis)&lt;br /&gt;
*[[Influenza]] and other viral respiratory infections&lt;br /&gt;
*'''Organic dust toxic syndrome (ODTS)''' — '''the critical ED differential'''; occurs after heavy organic dust exposure with identical flu-like symptoms; differs from HP because: (1) CXR is '''normal''' (no infiltrates), (2) severe hypoxemia does not occur, (3) '''no prior sensitization required''' (can occur on first exposure), (4) no long-term sequelae; ODTS is '''30–50 times more common''' than farmer's lung&amp;lt;ref name=&amp;quot;VonEssen&amp;quot;&amp;gt;Von Essen SG, et al. Organic dust toxic syndrome: an acute febrile reaction to organic dust exposure distinct from hypersensitivity pneumonitis. ''Clin Toxicol''. 1990;28(4):389-420.&amp;lt;/ref&amp;gt;&lt;br /&gt;
*Metal fume fever (zinc, copper exposure — similar flu-like presentation hours after exposure)&lt;br /&gt;
*Inhalation fever (self-limited; no CXR infiltrates; no sequelae)&amp;lt;ref name=&amp;quot;Medscape&amp;quot;/&amp;gt;&lt;br /&gt;
*[[Silo filler's disease]] (nitrogen dioxide exposure — distinct toxicant, different mechanism)&lt;br /&gt;
*[[Pulmonary embolism]]&lt;br /&gt;
&lt;br /&gt;
'''Chronic HP differential:'''&lt;br /&gt;
*[[Idiopathic pulmonary fibrosis]] (UIP pattern; '''basal predominant'''; no exposure history; no granulomas; no air trapping)&lt;br /&gt;
*[[Sarcoidosis]] (well-formed granulomas; hilar lymphadenopathy prominent on CXR; non-caseating but along bronchovascular bundle, not bronchiolocentric)&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;/&amp;gt;&lt;br /&gt;
*Non-specific interstitial pneumonia (NSIP)&lt;br /&gt;
*Cryptogenic organizing pneumonia (COP/BOOP)&lt;br /&gt;
*[[Bronchiolitis obliterans]]&lt;br /&gt;
*Connective tissue disease–associated ILD&lt;br /&gt;
*Drug-induced pneumonitis ([[methotrexate]], [[amiodarone]], [[nitrofurantoin]], [[bleomycin]])&lt;br /&gt;
*[[Tuberculosis]] (caseating granulomas; positive AFB)&lt;br /&gt;
*Lymphocytic interstitial pneumonia (LIP)&lt;br /&gt;
*Allergic bronchopulmonary aspergillosis (ABPA)&lt;br /&gt;
&lt;br /&gt;
{{Template:SOB DDX}}&lt;br /&gt;
&lt;br /&gt;
==Evaluation==&lt;br /&gt;
===Workup===&lt;br /&gt;
'''Laboratory (ED):'''&lt;br /&gt;
*CBC: leukocytosis with '''left shift and neutrophilia''' in acute HP; eosinophilia is NOT typical (its presence suggests ABPA, eosinophilic pneumonia, or parasitic disease)&lt;br /&gt;
*[[CRP]]/[[ESR]]: elevated in acute HP&lt;br /&gt;
*[[Basic metabolic panel]], lactate&lt;br /&gt;
*ABG/VBG: hypoxemia; may show widened A-a gradient; severe acute HP can cause significant respiratory failure&lt;br /&gt;
*Procalcitonin: may help differentiate from bacterial [[pneumonia]] (often low in HP, elevated in bacterial infection)&lt;br /&gt;
*'''Serum-specific IgG antibodies (precipitins):''' NOT an ED test, but understand their limitations — positive results reflect '''exposure/sensitization, not necessarily disease''' (~40% of pigeon breeders have positive IgG without clinical HP); false negatives are common because the offending antigen may not be in the test panel&amp;lt;ref name=&amp;quot;EMCrit&amp;quot;&amp;gt;Hypersensitivity Pneumonitis (HP). ''EMCrit/IBCC''. Updated August 2025.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Imaging:'''&lt;br /&gt;
&lt;br /&gt;
''Chest X-ray:''&lt;br /&gt;
*Acute HP: diffuse '''bilateral reticulonodular''' or ground-glass infiltrates; may be normal in mild disease&amp;lt;ref name=&amp;quot;Medscape&amp;quot;/&amp;gt;&lt;br /&gt;
*Chronic HP: reticulonodular pattern, fibrotic changes, volume loss (upper/mid-zone predominance may help distinguish from IPF)&lt;br /&gt;
*'''ODTS:''' CXR is '''normal''' — this is the key imaging distinction from acute HP&amp;lt;ref name=&amp;quot;VonEssen&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
''High-resolution CT (HRCT) — the key imaging study:''&lt;br /&gt;
&lt;br /&gt;
''Non-fibrotic HP:''&lt;br /&gt;
*'''Profuse ground-glass centrilobular nodules''' — often described as &amp;quot;fluffy&amp;quot; or &amp;quot;rosette&amp;quot; pattern; '''essentially diagnostic''' in the appropriate clinical context&amp;lt;ref name=&amp;quot;EMCrit&amp;quot;/&amp;gt;&lt;br /&gt;
*Diffuse ground-glass opacities&lt;br /&gt;
*Air trapping on expiratory images (mosaic attenuation)&lt;br /&gt;
*Upper/mid-lung predominance (unlike IPF which is basal-predominant)&lt;br /&gt;
&lt;br /&gt;
''Fibrotic HP:''&lt;br /&gt;
*Reticular pattern, traction bronchiectasis, honeycombing (but honeycombing is usually minimal and '''not basal-predominant''' unlike IPF)&lt;br /&gt;
*'''Three-density pattern''' (previously called &amp;quot;head cheese sign&amp;quot;): coexisting areas of ground-glass opacity, normal lung, and air trapping (low attenuation) — '''highly suggestive of fibrotic HP over IPF'''&amp;lt;ref name=&amp;quot;ATS2020&amp;quot;/&amp;gt;&lt;br /&gt;
*Air trapping on expiratory CT in ≥3 lobes bilaterally is '''inconsistent with IPF''' and favors HP&amp;lt;ref name=&amp;quot;EMCrit&amp;quot;/&amp;gt;&lt;br /&gt;
*Upper/mid-zone fibrosis (vs. basal in UIP/IPF)&lt;br /&gt;
*Centrilobular nodules may still be visible (~50% of cases)&amp;lt;ref name=&amp;quot;EMCrit&amp;quot;/&amp;gt;&lt;br /&gt;
*Mild mediastinal lymphadenopathy may occur (usually &amp;lt;15 mm, 1–2 nodes)&amp;lt;ref name=&amp;quot;EMCrit&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Pulmonary function tests''' (not performed in ED, but understand the pattern):&lt;br /&gt;
*Classically '''restrictive''' pattern (reduced FVC, reduced TLC) with reduced DLCO&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;/&amp;gt;&lt;br /&gt;
*May also show '''obstructive''' or '''mixed''' pattern (especially with air trapping component)&lt;br /&gt;
*Reduced DLCO is common in both fibrotic and non-fibrotic HP&lt;br /&gt;
&lt;br /&gt;
'''Bronchoalveolar lavage (BAL)''' (outpatient/inpatient — not ED):&lt;br /&gt;
*'''Lymphocytosis''' (often &amp;gt;50%) with '''low CD4:CD8 ratio''' supports HP&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;/&amp;gt;&lt;br /&gt;
*Helps distinguish from sarcoidosis (normal cell count, high CD4:CD8) and IPF (neutrophilia, not lymphocytosis)&lt;br /&gt;
*Lymphocytosis may be absent in chronic/fibrotic HP&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Diagnosis===&lt;br /&gt;
*'''No single test is diagnostic''' — HP requires integration of clinical history, exposure assessment, imaging, and sometimes BAL and/or biopsy through '''multidisciplinary discussion (MDD)'''&amp;lt;ref name=&amp;quot;ATS2020&amp;quot;/&amp;gt;&lt;br /&gt;
*The 2020 ATS/JRS/ALAT guideline provides a diagnostic confidence framework combining: (1) identified exposure, (2) characteristic HRCT pattern, (3) BAL lymphocytosis, and (4) histopathology when needed&amp;lt;ref name=&amp;quot;ATS2020&amp;quot;/&amp;gt;&lt;br /&gt;
*'''In the ED, focus on:'''&lt;br /&gt;
**(1) Recognizing the clinical pattern — recurrent flu-like illness temporally linked to specific environments, or progressive ILD with exposure history&lt;br /&gt;
**(2) Obtaining a '''thorough exposure history''' (occupation, hobbies, home environment, pets, bedding, hot tubs, HVAC)&lt;br /&gt;
**(3) Ordering HRCT (or at minimum CXR) and basic labs&lt;br /&gt;
**(4) Communicating suspicion to the admitting team or arranging outpatient pulmonology referral&lt;br /&gt;
*Surgical lung biopsy is reserved for cases where confident diagnosis cannot be reached after clinical evaluation, imaging, and BAL&amp;lt;ref name=&amp;quot;ATS2020&amp;quot;/&amp;gt;&lt;br /&gt;
*Transbronchial cryobiopsy is increasingly used as a less invasive alternative with reasonable yield&amp;lt;ref name=&amp;quot;ATS2020&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Management==&lt;br /&gt;
'''1. Antigen avoidance — the single most important intervention'''&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;/&amp;gt;&lt;br /&gt;
*Identify and eliminate the causative exposure&lt;br /&gt;
*Occupational: workplace modification, personal protective equipment (N95 mask), job change if necessary&lt;br /&gt;
*Domestic: remove birds, replace feather bedding, remediate mold/water damage, clean or replace HVAC systems and humidifiers, maintain hot tubs properly&lt;br /&gt;
*'''Nonfibrotic HP is often fully reversible''' if antigen exposure is eliminated early&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2. Corticosteroids — hasten recovery but do not change long-term prognosis if exposure continues'''&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;/&amp;gt;&lt;br /&gt;
*'''Acute HP:''' Prednisone 0.5–1 mg/kg/day for 1–2 weeks, then taper&amp;lt;ref name=&amp;quot;Medscape2&amp;quot;&amp;gt;Hypersensitivity Pneumonitis Treatment. ''Medscape/eMedicine''. Updated 2024.&amp;lt;/ref&amp;gt;&lt;br /&gt;
*'''Subacute/chronic HP:''' Prednisone 0.5–1 mg/kg/day for 4–8 weeks, then gradual taper to maintenance ~10 mg/day or off, guided by clinical response and PFTs&amp;lt;ref name=&amp;quot;Medscape2&amp;quot;/&amp;gt;&lt;br /&gt;
*Note: '''No randomized controlled trials''' demonstrate long-term benefit of corticosteroids in HP; they improve short-term lung function but without antigen avoidance, disease will recur&amp;lt;ref name=&amp;quot;StatPearls&amp;quot;/&amp;gt;&lt;br /&gt;
*'''Mild acute HP may resolve spontaneously''' with antigen avoidance alone — corticosteroids are not always required&lt;br /&gt;
&lt;br /&gt;
'''3. ED management of acute presentation:'''&lt;br /&gt;
*Supplemental O2 to maintain SpO2 &amp;gt;92%&lt;br /&gt;
*Corticosteroids if moderate-to-severe respiratory impairment (methylprednisolone IV or prednisone PO)&lt;br /&gt;
*Consider empiric antibiotics pending workup if [[pneumonia]] cannot be excluded (HP and infection are often indistinguishable early)&lt;br /&gt;
*Do NOT dismiss recurrent &amp;quot;flu-like illness&amp;quot; in a farmer, bird keeper, or hot tub user — '''ask about exposure history and symptom timing'''&lt;br /&gt;
&lt;br /&gt;
'''4. Outpatient management (coordinate with pulmonology):'''&lt;br /&gt;
*'''Steroid-sparing immunosuppression''' for chronic HP with ongoing inflammation: mycophenolate mofetil or azathioprine&amp;lt;ref name=&amp;quot;ERJ&amp;quot;&amp;gt;Costabel U, et al. Diagnosis, course and management of hypersensitivity pneumonitis. ''Eur Respir Rev''. 2022;31(163):210169.&amp;lt;/ref&amp;gt;&lt;br /&gt;
*'''Antifibrotic therapy''' for progressive fibrotic HP (progressive pulmonary fibrosis phenotype): nintedanib (INBUILD trial) slows FVC decline; pirfenidone is an alternative&amp;lt;ref name=&amp;quot;Merck&amp;quot;/&amp;gt;&lt;br /&gt;
*PCP prophylaxis should be considered for patients on dual immunosuppression or &amp;gt;20 mg prednisone chronically&amp;lt;ref name=&amp;quot;AJRCCM2017&amp;quot;&amp;gt;Salisbury ML, et al. Diagnosis and treatment of fibrotic hypersensitivity pneumonia. ''Am J Respir Crit Care Med''. 2017;196(6):690-699.&amp;lt;/ref&amp;gt;&lt;br /&gt;
*Pulmonary rehabilitation, supplemental O2 as needed&lt;br /&gt;
*Lung transplantation for end-stage fibrotic HP refractory to all therapy&lt;br /&gt;
&lt;br /&gt;
==Disposition==&lt;br /&gt;
*'''Admit:'''&lt;br /&gt;
**Respiratory failure or significant hypoxemia (new O2 requirement)&lt;br /&gt;
**Severe acute HP with high fever, tachypnea, and respiratory distress&lt;br /&gt;
**Diagnostic uncertainty — cannot exclude [[pneumonia]], [[pulmonary embolism]], or other life-threatening cause&lt;br /&gt;
**Known HP with acute exacerbation not responding to initial treatment&lt;br /&gt;
**Chronic HP with acute deterioration in functional status&lt;br /&gt;
*'''Discharge with close follow-up:'''&lt;br /&gt;
**Mild acute HP with adequate oxygenation, improving on corticosteroids, and identifiable antigen source that can be immediately avoided&lt;br /&gt;
**Suspected HP with stable vital signs and adequate oxygenation — arrange:&lt;br /&gt;
***HRCT if not performed in ED&lt;br /&gt;
***Outpatient pulmonology referral within 1–2 weeks&lt;br /&gt;
***Outpatient PFTs&lt;br /&gt;
**'''Specific discharge counseling:'''&lt;br /&gt;
***'''Identify and avoid the exposure''' — this is the most important instruction&lt;br /&gt;
***Return for worsening dyspnea, fever, or inability to maintain oral intake&lt;br /&gt;
***Do not return to the implicated environment (barn, bird room, workplace, hot tub) until seen by pulmonology&lt;br /&gt;
***Begin prednisone taper if prescribed, with PCP follow-up for monitoring&lt;br /&gt;
&lt;br /&gt;
==See Also==&lt;br /&gt;
*[[Bronchiolitis obliterans]]&lt;br /&gt;
*[[Idiopathic pulmonary fibrosis]]&lt;br /&gt;
*[[Sarcoidosis]]&lt;br /&gt;
*[[Pneumonia]]&lt;br /&gt;
*[[Smoke inhalation]]&lt;br /&gt;
*[[Asthma]]&lt;br /&gt;
*[[Occupational asthma]]&lt;br /&gt;
*[[Eosinophilic pneumonia]]&lt;br /&gt;
&lt;br /&gt;
==External Links==&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/books/NBK499918/ Hypersensitivity Pneumonitis — StatPearls]&lt;br /&gt;
*[https://emcrit.org/ibcc/hp/ Hypersensitivity Pneumonitis — EMCrit/IBCC]&lt;br /&gt;
*[https://www.atsjournals.org/doi/full/10.1164/rccm.202005-2032ST ATS/JRS/ALAT Clinical Practice Guideline: Diagnosis of HP (2020)]&lt;br /&gt;
*[https://www.merckmanuals.com/professional/pulmonary-disorders/interstitial-lung-diseases/hypersensitivity-pneumonitis Hypersensitivity Pneumonitis — Merck Manual Professional]&lt;br /&gt;
*[https://www.lung.org/lung-health-diseases/lung-disease-lookup/hypersensitivity-pneumonitis/learn-about-hypersensitivity Hypersensitivity Pneumonitis — American Lung Association]&lt;br /&gt;
*[https://publications.ersnet.org/content/errev/31/163/210169 Diagnosis, Course and Management of HP — European Respiratory Review (2022)]&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category:Pulmonary]]&lt;/div&gt;</summary>
		<author><name>Ostermayer</name></author>
	</entry>
</feed>